| 000 | 00966 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250518021806.0 | ||
| 264 | 0 | _c20200103 | |
| 008 | 202001s 0 0 eng d | ||
| 022 | _a1097-0142 | ||
| 024 | 7 |
_a10.1002/cncr.31960 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMaraka, Stefania | |
| 245 | 0 | 0 |
_aReply to Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma. _h[electronic resource] |
| 260 |
_bCancer _c04 2019 |
||
| 300 |
_a1385-1386 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aGlioblastoma |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMefloquine |
| 650 | 0 | 4 | _aMemantine |
| 650 | 0 | 4 | _aMetformin |
| 650 | 0 | 4 | _aTemozolomide |
| 700 | 1 | _aGroves, Morris D | |
| 700 | 1 | _aPenas-Prado, Marta | |
| 773 | 0 |
_tCancer _gvol. 125 _gno. 8 _gp. 1385-1386 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.31960 _zAvailable from publisher's website |
| 999 |
_c29317532 _d29317532 |
||